IMRA IMARA Inc. Stock Quote

IMRA [NASD]

Index	-	P/E	-	EPS (ttm)	-2.39	Insider Own	2.90%	Shs Outstand	26.29M	Perf Week	7.69%
Market Cap	32.80M	Forward P/E	-	EPS next Y	-0.68	Insider Trans	-43.13%	Shs Float	21.83M	Perf Month	-8.70%
Income	-55.80M	PEG	-	EPS next Q	-0.58	Inst Own	61.20%	Short Float	1.22%	Perf Quarter	-11.89%
Sales	-	P/S	-	EPS this Y	32.90%	Inst Trans	-5.96%	Short Ratio	0.70	Perf Half Y	-62.39%
Book/sh	2.75	P/B	0.46	EPS next Y	64.60%	ROA	-62.90%	Target Price	4.33	Perf Year	-83.89%
Cash/sh	2.80	P/C	0.45	EPS next 5Y	-	ROE	-69.10%	52W Range	0.97 - 9.29	Perf YTD	-44.00%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-85.90%	Beta	-
Dividend %	-	Quick Ratio	10.90	Sales past 5Y	-	Gross Margin	-	52W Low	34.51%	ATR	0.12
Employees	41	Current Ratio	10.90	Sales Q/Q	-	Oper. Margin	-	RSI (14)	51.51	Volatility	7.68% 9.41%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	4.60%	Profit Margin	-	Rel Volume	0.06	Prev Close	1.26
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Mar 15 BMO	Payout	-	Avg Volume	381.80K	Price	1.31
Recom	2.70	SMA20	2.58%	SMA50	-8.65%	SMA200	-50.89%	Volume	2,024	Change	3.97%

Aug-11-21

Downgrade

Morgan Stanley

Overweight → Equal-Weight

$33 → $12

May-12-21

Resumed

Citigroup

Buy

$30

Aug-17-20

Upgrade

Citigroup

Neutral → Buy

$34 → $30

Jun-30-20

Downgrade

Citigroup

Buy → Neutral

$30 → $34

Apr-06-20

Initiated

SVB Leerink

Outperform

$25

Apr-06-20

Initiated

Morgan Stanley

Overweight

$35

Apr-06-20

Initiated

Cowen

Outperform

$25

May-19-22 12:00PM	What Makes IMARA Inc. (IMRA) a New Buy Stock Zacks
Apr-05-22 06:45AM	Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia GlobeNewswire -22.09%
Mar-15-22 07:00AM	Imara Reports Full Year 2021 Financial Results and Business Highlights GlobeNewswire +9.72%
Mar-09-22 06:24AM	7 Biotech Stocks With Key Catalysts in March InvestorPlace
Mar-08-22 07:00AM	Imara to Webcast Conference Call of Full Year 2021 Financial Results and Business Highlights GlobeNewswire
Feb-19-22 07:10AM	David Mott Is The Independent Chairman of IMARA Inc. (NASDAQ:IMRA) And They Just Picked Up 144% More Shares Simply Wall St.
Feb-10-22 07:00AM	Imara to Present at 11th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
Jan-25-22 11:03AM	Imara To Start Testing Tovinontrine In Heart Failure Patients Benzinga
07:00AM	Imara Announces FDA Clearance of Investigational New Drug Application (IND) for Tovinontrine (IMR-687) for Heart Failure with Preserved Ejection Fraction (HFpEF) GlobeNewswire
Jan-05-22 07:00AM	Imara to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference GlobeNewswire -10.46%
Dec-14-21 07:00AM	Imara Presents Preclinical Data on IMR-261 at the American Society of Hematology (ASH) Annual Meeting 2021 GlobeNewswire -11.51%
Dec-13-21 07:00AM	Imara Presents Clinical and Preclinical Tovinontrine (IMR-687) Data at the American Society of Hematology (ASH) Annual Meeting 2021 GlobeNewswire
Nov-22-21 10:36AM	Imara Changes Primary Endpoint In Mid-Stage Sickle Cell Disease Trial Benzinga
07:00AM	Imara Announces Primary Endpoint Change in the Ardent Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Sickle Cell Disease GlobeNewswire
Nov-16-21 02:30PM	7 Penny Stocks to Book Profits on Before 2022 InvestorPlace -8.77%
11:34AM	Imara's Thalassemia Candidate Shows Reduced Transfusion Burden At Higher Dose Benzinga
07:00AM	Imara Announces Interim Analysis Data from Forte Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Transfusion-Dependent Subjects with Beta-thalassemia GlobeNewswire
Nov-09-21 07:00AM	Imara Reports Third Quarter 2021 Financial Results and Business Highlights GlobeNewswire +5.39%
Nov-08-21 07:00AM	Imara to Report Data Demonstrating the Potential of Tovinontrine (IMR-687) for the Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF) GlobeNewswire
Nov-04-21 04:01PM	Imara to Webcast Conference Call of Third Quarter 2021 Financial Results and Business Highlights GlobeNewswire
09:17AM	Imara to Present Clinical and Preclinical Data at the American Society of Hematology (ASH) Annual Meeting 2021 GlobeNewswire
Sep-15-21 07:00AM	Imara to Participate in Upcoming Investor Conferences GlobeNewswire +5.60%
Sep-06-21 08:08AM	What Type Of Shareholders Make Up IMARA Inc.'s (NASDAQ:IMRA) Share Registry? Simply Wall St.
Sep-03-21 07:00AM	Imara to Present at Upcoming Investor Conferences GlobeNewswire +6.34%
Aug-06-21 07:00AM	Imara Reports Second Quarter 2021 Financial Results and Business Highlights GlobeNewswire
Aug-05-21 07:15AM	Imara Announces Completion of Patient Enrollment in Ardent Phase 2b Clinical Trial of IMR-687 (tovinontrine) for Sickle Cell Disease GlobeNewswire +5.38%
Aug-02-21 06:07PM	3 Stocks Flashing Signs of Strong Insider Buying TipRanks
Jul-30-21 07:00AM	Imara to Webcast Conference Call of Second Quarter 2021 Financial Results and Business Highlights GlobeNewswire
Jul-14-21 06:59AM	Imara Raises $50M In Equity Funding To Support Development Of Sickle Cell Treatment Candidate Benzinga -16.78%
Jul-13-21 10:58PM	Imara Announces Pricing of Public Offering GlobeNewswire
04:01PM	Imara Announces Launch of Proposed Public Offering GlobeNewswire
Jun-30-21 07:00AM	Imara Announces Appointment of Laura A. Williams, M.D., MPH to Board of Directors GlobeNewswire
Jun-23-21 02:58PM	Hedge Fund Sentiment Is Stagnant On IMARA Inc. (IMRA) Insider Monkey
Jun-17-21 07:00AM	Imara Announces Recipients of the Second Annual Real Impact Grants Program to Support People Affected by Rare Genetic Blood Disorders GlobeNewswire
Jun-11-21 03:00AM	Imara Presents Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Congress GlobeNewswire
Jun-08-21 04:41AM	We Think IMARA (NASDAQ:IMRA) Needs To Drive Business Growth Carefully Simply Wall St. +8.26%
Jun-04-21 07:00AM	Imara to Present Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Congress GlobeNewswire
May-11-21 07:00AM	Imara Reports First Quarter 2021 Financial Results and Business Highlights GlobeNewswire +7.34%
06:30AM	Imara Inc to Host Earnings Call ACCESSWIRE
May-04-21 07:00AM	Imara to Webcast Conference Call of First Quarter 2021 Financial Results and Business Highlights GlobeNewswire
Mar-29-21 07:00AM	Imara Opens Applications for the Second-Annual Real Impact Community Support Program to Address Unmet Needs Affecting People with Rare Genetic Blood Disorders GlobeNewswire
Mar-22-21 04:05PM	SHAREHOLDER ALERT: Investigation of IMARA Inc. Announced by Holzer & Holzer, LLC Newsfile
Mar-17-21 07:00AM	Imara Announces Opening of Higher Dose Arms in Global Phase 2b Clinical Trials of IMR-687 for Sickle Cell Disease and Beta-Thalassemia GlobeNewswire
Mar-15-21 11:00AM	Bronstein, Gewirtz & Grossman, LLC Announces Investigation of IMARA, Inc. (IMRA) and Encourages Investors to Contact the Firm ACCESSWIRE +6.44%
Mar-14-21 08:16PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of IMARA, Inc. - IMRA Newsfile
Mar-12-21 05:45AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of IMARA, Inc. - IMRA CNW Group
Mar-10-21 02:40AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of IMARA, Inc. - IMRA PR Newswire
02:40AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of IMARA, Inc. - IMRA CNW Group
Mar-05-21 07:00AM	Imara Reports Full Year 2020 Financial Results and Business Highlights GlobeNewswire -19.01%
06:30AM	Imara Inc to Host Earnings Call ACCESSWIRE
Feb-26-21 09:30PM	Imara to Webcast Conference Call of Full Year 2020 Financial Results and Business Highlights GlobeNewswire
Feb-19-21 07:00AM	Imara to Present at SVB Leerink 10th Annual Global Healthcare Conference GlobeNewswire
Jan-20-21 07:00AM	Imara Announces the Appointment of Kenneth Attie, M.D. as Chief Medical Officer GlobeNewswire
Jan-06-21 05:21PM	Imara Analyst Says Buy The Weakness Ahead Of Multiple 2021 Data Readouts Benzinga -37.97%
07:00AM	Imara Reports Phase 2a Clinical Trial Results of IMR-687 in Adult Patients with Sickle Cell Disease GlobeNewswire
Dec-10-20 01:01AM	We Think IMARA (NASDAQ:IMRA) Can Afford To Drive Business Growth Simply Wall St. -7.63%
Dec-07-20 07:00AM	Imara Presents IMR-687 Phase 2a Open Label Extension Case Reports on Two Patients with Sickle Cell Disease at the 62nd ASH Annual Meeting and Exposition GlobeNewswire
Nov-30-20 10:36PM	Do Hedge Funds Love IMARA Inc. (IMRA)? Insider Monkey -12.03%
07:00AM	Imara to Present Clinical Data on IMR-687 as Monotherapy and in Combination with Hydroxyurea in Patients with Sickle Cell Disease at the 62nd ASH Annual Meeting and Exposition GlobeNewswire
Nov-17-20 07:00AM	Imara Announces the Appointment of Lynette Hopkinson as Senior Vice President of Regulatory GlobeNewswire
Nov-05-20 07:00AM	Imara Reports Third Quarter 2020 Financial Results and Business Highlights GlobeNewswire
Oct-31-20 08:00AM	Kaskela Law LLC Announces Stockholder Investigation of Imara Inc. - IMRA ACCESSWIRE
Oct-29-20 07:00AM	Imara to Webcast Conference Call of Third Quarter Financial Results GlobeNewswire
Oct-16-20 07:00AM	Imara Announces First Patient Dosed in Forte Phase 2b Clinical Trial of IMR-687 in Beta-Thalassemia GlobeNewswire
Sep-02-20 07:00AM	Imara to Present at Upcoming Investor Conferences GlobeNewswire
Aug-25-20 07:00AM	Imara Receives Orphan Drug Designation from the European Commission for IMR-687 for the Treatment of Sickle Cell Disease GlobeNewswire
Aug-14-20 08:26AM	The Daily Biotech Pulse: Adcom Rules In Favor Of Mesoblast, CureVac IPO, Novavax Clinches UK COVID-19 Vaccine Deal Benzinga
07:00AM	Imara Reports Second Quarter 2020 Financial Results and Business Highlights GlobeNewswire
Aug-13-20 04:01PM	Imara Announces First Patient Dosed in Ardent Phase 2b Clinical Trial of IMR-687 in Sickle Cell Disease GlobeNewswire
Aug-07-20 07:00AM	Imara to Webcast Conference Call of Second Quarter 2020 Financial Results GlobeNewswire
Jul-30-20 07:00AM	Imara Announces IMR-687 Granted Fast Track Designation and Rare Pediatric Disease Designation for Treatment of Beta-Thalassemia GlobeNewswire
Jun-29-20 04:01PM	Imara Added to Membership of U.S. Small-Cap Russell 2000® Index GlobeNewswire -16.80%
Jun-25-20 07:00AM	Imara Announces Recipients of Real Impact Grants Program to Support People Affected by Rare Genetic Blood Disorders GlobeNewswire
Jun-24-20 07:00AM	Imara Receives Orphan Drug Designation for IMR-687 for Treatment of Beta-thalassemia GlobeNewswire -6.03%
Jun-22-20 01:57PM	Here is What Hedge Funds Think About IMARA Inc. (IMRA) Insider Monkey -5.98%
Jun-13-20 08:44AM	Here's Why We're Not Too Worried About IMARA's (NASDAQ:IMRA) Cash Burn Situation Simply Wall St.
Jun-12-20 07:46AM	Imara reports promising data from mid-stage trial for sickle cell treatment MarketWatch -16.62%
07:00AM	Imara Presents Positive Interim Results from Phase 2a Study of IMR-687 in Sickle Cell Disease at the Virtual European Hematology Association Annual Congress GlobeNewswire
May-21-20 07:00AM	Imara to Present Data on IMR-687 in Sickle Cell Disease at the 25th Annual European Hematology Association (EHA) Congress GlobeNewswire
May-07-20 07:00AM	Imara Reports First Quarter 2020 Financial Results and Business Highlights GlobeNewswire -11.50%
May-06-20 07:00AM	Imara Launches Real Impact Community Support Program to Address Unmet Needs Affecting People with Rare Genetic Blood Disorders GlobeNewswire -5.83%
May-04-20 07:00AM	Imara Announces Appointment of Stephen M. Migausky as General Counsel GlobeNewswire +5.62%
Apr-23-20 07:00AM	Imara Strengthens Board of Directors With Appointment of Edward R. Conner, M.D. GlobeNewswire
Mar-11-20 09:57PM	IMARA Announces Pricing of Initial Public Offering GlobeNewswire

IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Leonard Braden Michael	10% Owner	May 17	Buy	1.26	26,145	32,836	2,901,145	May 18 11:00 AM
Leonard Braden Michael	10% Owner	May 16	Buy	1.17	15,000	17,577	2,875,000	May 18 11:00 AM
Leonard Braden Michael	10% Owner	Apr 22	Buy	1.38	8,000	11,040	2,860,000	Apr 25 11:05 AM
Leonard Braden Michael	10% Owner	Apr 21	Buy	1.40	552,000	772,800	2,852,000	Apr 25 11:05 AM
New Enterprise Associates 14,	10% Owner	Apr 06	Sale	1.10	255,463	281,827	2,611,050	Apr 07 04:54 PM
New Enterprise Associates 14,	10% Owner	Apr 05	Sale	1.07	439,088	469,429	2,866,513	Apr 07 04:54 PM
MOTT DAVID M	Director	Feb 23	Buy	1.46	35,257	51,475	229,224	Feb 23 07:12 PM
MOTT DAVID M	Director	Feb 22	Buy	1.56	65,817	102,675	193,967	Feb 23 07:12 PM
MOTT DAVID M	Director	Feb 18	Buy	1.30	50,398	65,517	128,150	Feb 23 07:12 PM
MOTT DAVID M	Director	Feb 17	Buy	1.17	14,595	17,076	77,752	Feb 17 07:21 PM
MOTT DAVID M	Director	Feb 16	Buy	1.20	11,779	14,135	63,157	Feb 17 07:21 PM
MOTT DAVID M	Director	Feb 15	Buy	1.20	19,552	23,462	51,378	Feb 17 07:21 PM
MOTT DAVID M	Director	Feb 14	Buy	1.18	8,500	10,030	31,826	Feb 14 05:02 PM
MOTT DAVID M	Director	Feb 11	Buy	1.23	14,573	17,925	23,326	Feb 14 05:02 PM
MOTT DAVID M	Director	Feb 10	Buy	1.29	8,753	11,291	8,753	Feb 14 05:02 PM
New Enterprise Associates 14,	10% Owner	Jan 25	Sale	1.47	102,952	151,803	3,305,601	Jan 25 08:41 PM
New Enterprise Associates 14,	10% Owner	Jan 24	Sale	1.55	19,984	31,017	3,408,553	Jan 25 08:41 PM
New Enterprise Associates 14,	10% Owner	Jan 21	Sale	1.67	11,622	19,389	3,428,537	Jan 25 08:41 PM
New Enterprise Associates 14,	10% Owner	Jan 20	Sale	1.81	6,295	11,385	3,440,159	Jan 20 05:20 PM
New Enterprise Associates 14,	10% Owner	Jan 19	Sale	1.82	13,412	24,414	3,446,454	Jan 20 05:20 PM
New Enterprise Associates 14,	10% Owner	Jan 18	Sale	1.89	6,848	12,927	3,459,866	Jan 20 05:20 PM
New Enterprise Associates 14,	10% Owner	Jan 14	Sale	1.91	9,707	18,583	3,466,714	Jan 14 05:04 PM
New Enterprise Associates 14,	10% Owner	Jan 13	Sale	1.93	7,209	13,886	3,476,421	Jan 14 05:04 PM
New Enterprise Associates 14,	10% Owner	Jan 12	Sale	2.02	4,634	9,357	3,483,630	Jan 14 05:04 PM
New Enterprise Associates 14,	10% Owner	Jan 11	Sale	2.04	2,409	4,919	3,488,264	Jan 11 05:54 PM
New Enterprise Associates 14,	10% Owner	Jan 10	Sale	2.00	1,751	3,502	3,490,673	Jan 11 05:54 PM
New Enterprise Associates 14,	10% Owner	Jan 07	Sale	2.08	14,600	30,318	3,492,424	Jan 11 05:54 PM
New Enterprise Associates 14,	10% Owner	Jan 06	Sale	2.16	10,257	22,205	3,507,024	Jan 06 05:35 PM
New Enterprise Associates 14,	10% Owner	Jan 05	Sale	2.25	8,200	18,439	3,517,281	Jan 06 05:35 PM
New Enterprise Associates 14,	10% Owner	Jan 04	Sale	2.34	13,459	31,544	3,525,481	Jan 06 05:35 PM
New Enterprise Associates 14,	10% Owner	Jan 03	Sale	2.34	44,665	104,396	3,538,940	Jan 03 08:15 PM
New Enterprise Associates 14,	10% Owner	Dec 31	Sale	2.25	49,953	112,409	3,583,605	Jan 03 08:15 PM
New Enterprise Associates 14,	10% Owner	Dec 30	Sale	2.29	21,858	50,066	3,633,558	Jan 03 08:15 PM
New Enterprise Associates 14,	10% Owner	Dec 29	Sale	2.30	15,196	34,954	3,655,416	Dec 29 06:35 PM
New Enterprise Associates 14,	10% Owner	Dec 28	Sale	2.34	24,580	57,539	3,670,612	Dec 29 06:35 PM
New Enterprise Associates 14,	10% Owner	Dec 27	Sale	2.42	27,651	67,007	3,695,192	Dec 29 06:35 PM
New Enterprise Associates 14,	10% Owner	Dec 23	Sale	2.41	23,961	57,746	3,722,843	Dec 27 04:34 PM
New Enterprise Associates 14,	10% Owner	Dec 22	Sale	2.32	20,109	46,679	3,746,804	Dec 27 04:34 PM
New Enterprise Associates 14,	10% Owner	Dec 21	Sale	2.32	41,222	95,804	3,766,913	Dec 27 04:34 PM
New Enterprise Associates 14,	10% Owner	Dec 20	Sale	2.26	85,123	192,604	3,808,135	Dec 27 04:34 PM
New Enterprise Associates 14,	10% Owner	Dec 16	Sale	2.23	44,993	100,546	3,893,258	Dec 27 04:34 PM
New Enterprise Associates 14,	10% Owner	Dec 15	Sale	2.28	28,817	65,685	3,938,251	Dec 27 04:34 PM
New Enterprise Associates 14,	10% Owner	Dec 14	Sale	2.56	15,093	38,643	3,967,068	Dec 27 04:34 PM
New Enterprise Associates 14,	10% Owner	Dec 13	Sale	2.83	17,501	49,558	3,982,161	Dec 27 04:34 PM
New Enterprise Associates 14,	10% Owner	Dec 10	Sale	2.83	8,667	24,541	3,999,662	Dec 27 04:34 PM
New Enterprise Associates 14,	10% Owner	Dec 09	Sale	2.95	5,666	16,693	4,008,329	Dec 27 04:34 PM
ORBIMED ADVISORS LLC	Director	Jul 16	Buy	6.00	1,666,666	9,999,996	1,666,666	Jul 16 04:27 PM
Bonita David P	Director	Jul 16	Buy	6.00	1,666,666	9,999,996	1,666,666	Jul 16 04:21 PM
Chin Mark	Director	Jul 16	Buy	6.00	1,333,333	7,999,998	2,344,072	Jul 28 08:50 AM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience